+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 21Years - 80Years
All Genders
ID07017634

Randomized Study of Novosis Putty Versus Standard Bone Graft in Single-Level Lumbar Fusion Surgery for Degenerative Disc Disease

Led by CGBio Inc. · Updated on 2026-08-26

316

Participants Needed

10

Research Sites

152 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of Novosis Putty compared to standard bone graft care in patients undergoing transforaminal lumbar interbody fusion TLIF surgery for lumbar degenerative disc disease. This pivotal, randomized, prospective, multi-center study focuses on adults aged 21 to 80 who have symptomatic lumbar degeneration confirmed by imaging and have not improved after at least six months of conservative treatment. Participants are randomly assigned to receive either TLIF surgery using Novosis Putty or the standard bone graft method. Both groups undergo single-level TLIF surgery, and treatments are administered in a double-blind fashion. The study includes a long-term follow-up period to assess various outcomes up to 60 months after surgery. During the trial, participants are assessed at multiple time points for overall success, fusion success, disability index scores ODI, pain levels VAS, quality of life SF-12, treatment satisfaction, and intraoperative variables. Follow-up visits occur at 6 weeks, 3, 6, 12, 24, 36, 48, and 60 months post-surgery. The primary outcome is overall success measured 24 months after surgery. Safety and efficacy are closely monitored throughout the study, which may last up to nearly six years.

CONDITIONS

Brief Title

Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients With Lumbar Degenerative Disc Disease

Research Team

J

Jumi Han

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here